Animal health biotechnology company BiomEdit Inc. announced it has received a Finding of No Significant Impact (FONSI) letter from the U.S. Department of Agriculture’s Animal & Plant Health Inspection Service for CPerf LLV* (BE-101), its lead candidate for the prevention of mortality caused by necrotic enteritis (NE) in broiler chickens. The milestone follows APHIS’s environmental and risk assessment of CPerf LLV* (BE-101) and advances the program to the final phase of evaluation.

After thorough evaluation, USDA concluded that the proposed field use of CPerf LLV* (BE-101) would not significantly impact the environment — issuing a FONSI — and cleared the product to proceed toward field safety trials. Once BiomEdit’s manufacturing partner, Diamond Animal Health, completes USDA requirements for pre-license serials, CPerf LLV* (BE-101) will be eligible for shipment to field sites for testing, targeted to begin in early first-quarter 2026.

“The FONSI letter represents another key regulatory milestone as we work to deliver a first-of-its-kind solution for poultry producers,” said Aaron Schacht, chief executive officer of BiomEdit. “Necrotic enteritis causes an estimated $6 billion in annual losses globally, yet producers have few effective non-antibiotic tools. CPerf LLV* (BE-101) has the potential to fill that gap with a practical, scalable biologic approach.”

CPerf LLV* (BE-101) is an engineered probiotic vectored antibody biologic designed to neutralize Clostridium perfringens toxins — the primary cause of NE-related mortality and productivity loss in poultry. In commercial-like challenge studies, CPerf LLV* (BE-101) demonstrated significant improvements in mortality reduction, feed conversion and bird weight gain.

Development progress: The CPerf LLV* (BE-101) development program remains on track for conditional licensure by the fourth quarter of 2026, with several key milestones recently achieved, including successful completion of engineering batches, initiation of pre-license serial batch manufacture (now at the halfway mark), and ongoing USDA review of the field safety study protocol.

Upon full licensure, CPerf LLV* (BE-101) will be commercialized under the brand name Optavant and will represent the first non-antibiotic biologic specifically designed to combat NE while improving flock health and production outcomes. BiomEdit is backed by Anterra Capital, Viking Global, Nutreco, AgriZeroNZ, Elevate, Betagro Ventures and other investors.

Source: Feedstuffs (Informa Markets)